Keywords
: Stomach Neoplasms
. Receptor
erbB-2
Immunohistochemistry
Prevalence
Colombia
. Receptor
erbB-2
Immunohistochemistry
Prevalence
Colombia
How to Cite
García Ramírez, C. A., Uribe Pérez, C. J., Niño Vargas, P. M., Salazar Radi, D. S., & Vásquez Pinto, L. E. (2013). Her-2/neu expression in gastric cancer in Bucaramanga metropolitan area between 2006 and 2009. Médicas UIS, 26(2). Retrieved from https://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/3650
Abstract
Introduction: gastric cancer has become a public health problem in the world and in Colombia is one of the leading causes of mortality.
The oncoprotein Her/2 neu has shown to be an independent bad prognostic factor with a variable expression ranging from 8 - 91% and has been associated with an aggressive disease and a lesser response to treatment. Aim: to determinate the frequency of Her/2 neu and its
expression in gastric carcinoma, also its histopathologic correlation in patients from the Bucaramanga Metropolitan Area during 2006 to 2009. Materials and methods: we conducted an observational cross-sectional study with a population of 409 cases from the Population
based Cancer Registry from Bucaramanga Metropolitan Area. The information was collected from clinical history and parafn blocks. The immunochemistry was made with manual HERCEPTEST method. Scores 0 and 1 were interpretated as negative, score 2 as equivocal and score 3 as positive. The samples that were equivocal underwent fuorescence immunohistochemistry in situ. Results: males predominated with 243 cases, the intestinal type was the more prevalent with 230 cases, Her/2 neu expression was positive in 46 cases and there was no signifcant statistical association with histopathological subtype or gender. Conclusions: expression of Her/2 neu was positive in 11.2% of gastric carcinomas of patients from Bucaramanga Metropolitan Area, this fnding is consistent with other reports, and neither there was any statistical signifcance association with subtype and gender. (MÉD.UIS.2013;26(2):21-8).
References
1. International Agency for Research on Cancer (IARC), World Health Organization (WHO). Cancer incidence and mortality worldwide in 2008. IARC Publ. 2008.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
3. Pardo Ramos C, Cendales Duarte R. Incidencia estimada y mortalidad por cáncer en Colombia 2002 -2006. Bogotá: Instituto Nacional de Cancerología; 2010.
4. Uribe CJ, Osma S, Herrera V. Cancer incidence and mortality in the Bucaramanga Metropolitan Area, 2003-2007. Colomb Med. 2012;43(4):290-7.
5. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours. IARC WHO. 2008;3:2000-320.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
7. Crew KD, Neugut Al. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:450-64.
8. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev. 1996;5(6): 477-81.
9. Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol. 1985;12(1):11-8.
10. Corley DA, Buffer PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in five continents database. Int J Epidemiol. 2001;30:1415-25.
11. Piñeros M, Hernández G, Bray F. Increasing mortality rates of common malignancies in Colombia: an emerging problem. Cancer. 2004;101(10):2285-92.
12. Huang XE, Tajima K, Hamajima N, Kodera Y, Yamamura Y, Xiang J, et al. Effects of dietary, drinking, and smoking habits on the prognosis of gastric cancer. Nutr Cancer. 2000;38:30-6.
13. Correa P. Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol. 1988;83:504-9.
14. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325(16):1132-6.
15. Shand AG, Taylor AC, Banerjee M, Lessels A, Coia J, Clark C, et al. Gastric fundic gland polyps in south-east Scotland: absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection. J Gastroenterol Hepatol. 2002;17:1161-4.
16. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158(3):1005-10.
17. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
18. Bosman F T, Carneiro F, Hrubran RH, Theise N D. Classification of Tumours of the Digestive System. IARC Monogr Eval Carcinog Risks Hum. 2010.
19. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB–2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232(4758):1644-6.
20. Coussens L, Yang-Feng Tl, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132-9.
21. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12.
22. Kaptain S, Tan LK, Chen B. Her–2/neu and breast cancer. Diagn Mol Pathol. 2001;10(3):139-52.
23. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, et al. Pathological features of advanced gastric cancer: relationship to human epidermal growth factor receptor 2 positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27(15s):4556.
24. Esquivel HO, Castelan ME, Espinoza BM. Expresión de Her2/neu en adenocarcinoma gástrico. Experiencia de 10 años (2001-2011) en la Unidad Médica de Alta Especialidad No.25, Centro Médico Nacional Noreste. Patol Rev Latinoam. 2012;50(2):80-6.
25. Painemal C, Berrios M, Gallegos I, San Martín C, Villanueva L, Barajas O, et al [sede web]. Determinación de la expresión del HER2 en Cáncer Gástrico: resultados preliminares. Revista chilena de cancerología y hematología. 2011;18(1):1-2. [actualizada el 31 de julio de 2012]. Disponible en: http://www.cancerologia.cl/revista.htm
26. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, Becker K, et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus. Cancer. 1994;73(7):1785-94.
27. Appelbaum FR. Acute myeloid leukemia in adults. En: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff ’s Clinical Oncology. 4 ed. Philadelphia: Elsevier; 2008. p. 2215-34.
28. Vallebuona SC. [sede web]. Primer informe Registro Poblacional de Cancer Chile 2003-2007. Ministerio de Salud. Disponible en: http://epi.minsal.cl/epi/0notransmisibles/cancer/INFORME%20RPC%20CHILE%202003-2007,%20UNIDAD%20VENT,%20DEPTO.EPIDEMIOLOGIA-MINSAL,13.04.2012.pdf
29. Esquivel O, Castelán EE, Espinoza MP. Expresión de Her-2/neu en adenocarcinoma gástrico. Experiencia de 10 años (2001-2011) en la Unidad Médica de Alta Especialidad No. 25, Centro Médico Nacional Noreste. Patología Rev Latinoam. 2012;50(2):80-6.
30. Beltran B, Yabar A. Expresión de HER2 en cáncer gástrico en el Perú. Rev Gastroenterol Peru. 2010;30(4):324-7.
31. Avital I, Pisters PWT, Kelsen DP, Willett CG. Cancer of the stomach, En: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9 ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011.
32. Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer. 1992;70(5):1030-7.
33. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-9.
34. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. Her-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol. 2000;31(1):35-9.
35. Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24(7):1754-61
36. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
3. Pardo Ramos C, Cendales Duarte R. Incidencia estimada y mortalidad por cáncer en Colombia 2002 -2006. Bogotá: Instituto Nacional de Cancerología; 2010.
4. Uribe CJ, Osma S, Herrera V. Cancer incidence and mortality in the Bucaramanga Metropolitan Area, 2003-2007. Colomb Med. 2012;43(4):290-7.
5. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours. IARC WHO. 2008;3:2000-320.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
7. Crew KD, Neugut Al. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:450-64.
8. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev. 1996;5(6): 477-81.
9. Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol. 1985;12(1):11-8.
10. Corley DA, Buffer PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in five continents database. Int J Epidemiol. 2001;30:1415-25.
11. Piñeros M, Hernández G, Bray F. Increasing mortality rates of common malignancies in Colombia: an emerging problem. Cancer. 2004;101(10):2285-92.
12. Huang XE, Tajima K, Hamajima N, Kodera Y, Yamamura Y, Xiang J, et al. Effects of dietary, drinking, and smoking habits on the prognosis of gastric cancer. Nutr Cancer. 2000;38:30-6.
13. Correa P. Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol. 1988;83:504-9.
14. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325(16):1132-6.
15. Shand AG, Taylor AC, Banerjee M, Lessels A, Coia J, Clark C, et al. Gastric fundic gland polyps in south-east Scotland: absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection. J Gastroenterol Hepatol. 2002;17:1161-4.
16. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158(3):1005-10.
17. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
18. Bosman F T, Carneiro F, Hrubran RH, Theise N D. Classification of Tumours of the Digestive System. IARC Monogr Eval Carcinog Risks Hum. 2010.
19. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB–2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232(4758):1644-6.
20. Coussens L, Yang-Feng Tl, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132-9.
21. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12.
22. Kaptain S, Tan LK, Chen B. Her–2/neu and breast cancer. Diagn Mol Pathol. 2001;10(3):139-52.
23. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, et al. Pathological features of advanced gastric cancer: relationship to human epidermal growth factor receptor 2 positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27(15s):4556.
24. Esquivel HO, Castelan ME, Espinoza BM. Expresión de Her2/neu en adenocarcinoma gástrico. Experiencia de 10 años (2001-2011) en la Unidad Médica de Alta Especialidad No.25, Centro Médico Nacional Noreste. Patol Rev Latinoam. 2012;50(2):80-6.
25. Painemal C, Berrios M, Gallegos I, San Martín C, Villanueva L, Barajas O, et al [sede web]. Determinación de la expresión del HER2 en Cáncer Gástrico: resultados preliminares. Revista chilena de cancerología y hematología. 2011;18(1):1-2. [actualizada el 31 de julio de 2012]. Disponible en: http://www.cancerologia.cl/revista.htm
26. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, Becker K, et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus. Cancer. 1994;73(7):1785-94.
27. Appelbaum FR. Acute myeloid leukemia in adults. En: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff ’s Clinical Oncology. 4 ed. Philadelphia: Elsevier; 2008. p. 2215-34.
28. Vallebuona SC. [sede web]. Primer informe Registro Poblacional de Cancer Chile 2003-2007. Ministerio de Salud. Disponible en: http://epi.minsal.cl/epi/0notransmisibles/cancer/INFORME%20RPC%20CHILE%202003-2007,%20UNIDAD%20VENT,%20DEPTO.EPIDEMIOLOGIA-MINSAL,13.04.2012.pdf
29. Esquivel O, Castelán EE, Espinoza MP. Expresión de Her-2/neu en adenocarcinoma gástrico. Experiencia de 10 años (2001-2011) en la Unidad Médica de Alta Especialidad No. 25, Centro Médico Nacional Noreste. Patología Rev Latinoam. 2012;50(2):80-6.
30. Beltran B, Yabar A. Expresión de HER2 en cáncer gástrico en el Perú. Rev Gastroenterol Peru. 2010;30(4):324-7.
31. Avital I, Pisters PWT, Kelsen DP, Willett CG. Cancer of the stomach, En: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9 ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011.
32. Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer. 1992;70(5):1030-7.
33. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-9.
34. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. Her-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol. 2000;31(1):35-9.
35. Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24(7):1754-61
36. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8.
Downloads
Download data is not yet available.